About the Company
Helios & Matheson Analytics, Inc. engages in the provision of information technology services and solutions. It operates through the following segments: Consulting, Technology, and Subscription. It serves to government, healthcare, financial, education and retail industries. The company was founded in February 1983 and is headquartered in New York, NY.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HMNY News
Helios Technologies Schedules First Quarter 2024 Financial Results Release and Conference Call
Thursday, May 9, 2024 9:00 a.m. Eastern Time Phone: (201) 689-8573 Internet webcast and accompanying slide presentation: ...
Fitzalan-Howard resigns as non-executive director of Helios board
Edward Fitzalan-Howard, Duke of Norfolk, has stepped down as non-executive director of the board at Lloyd's investment ...
Nashville Zoo Celebrates Arrival of Helios, A Tiny Leap for Red Ruffed Lemur Conservation
Nashville Zoo welcomed a newborn red ruffed lemur named Helios, a critical addition to this endangered species.
Helios Appoints Andrew Considine as Chief Technology Officer Ahead of 2024 Launch
Helios, an innovative Global Human Capital Management (HCM) and Payments platform redefining the Human Resources (HR) industry, has appointed Andrew Considine as Chief Technology Officer. Considine ...
Helios and King wrangle approval for Burlingame life science building
The San Francisco- and Boston-based developers won approval from the Burlingame Planning Commission for special permits for ...
Acer Predator Helios 16, Predator Helios Neo 16 Refreshed With 14th Gen Intel Core CPUs in India
Acer Predator Helios 16 and Helios Neo 16 laptops feature up to 16-inch WQXGA (1,600x2,560 pixels) IPS displays.
Acer Predator Helios 18
Acer’s Predator Helios 18 laptop (starts at $2,499.99; $3,099.99 as tested) joins its 18-inch competition as a super-powerful ...
Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace
As a closely watched readout from Alnylam Pharmaceuticals' Amvuttra in the rare heart disease transthyretin amyloid ...
Loading the latest forecasts...